Across TCGA pan-cancer cohorts, LPAR1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LPAR1 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher LPAR1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LPAR1 expression acts as an unfavorable survival marker.

GBM, LSCC, and LUAD are the cancer types where LPAR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.206	0.476	<.001	13	view →
LSCC	OS	Quartile	All	0.612	1.000	.043	1	view →
LUAD	OS	Tertile	II,III,IV	0.916	1.000	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: LPAR1 tumor-vs-normal RNA expression · all LPAR1 data types